BackZynerba Pharmaceuticals Overview

Zynerba Pharmaceuticals Selling, General & Admin

Selling, General & Admin expenses for ZYNE.

Quarterly SG&A Expenses

$3.97M
↑ 6.64% YoY

As of Jun 30, 2023

Annual SG&A Expenses (TTM)

$14.03M
↓ 7.44% YoY

Trailing 12 months ending Jun 30, 2023

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin